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Abstract
Background: Diabetes has been regarded as an inflammatory condition which is associated with left ventricular diastolic
dysfunction (LVDD). The purpose of this study was to examine the expression levels of macrophage migration inhibitory
factor (MIF) and G protein-coupled receptor kinase 2 (GRK2) in patients with early diabetic cardiomyopathy, and to
investigate the mechanisms involved in MIF expression and GRK2 activation.
Methods: 83 patients in the age range of 30-64 years with type 2 diabetes and 30 matched healthy men were recruited. Left
ventricular diastolic function was evaluated by cardiac Doppler echocardiography. Plasma MIF levels were determined by
ELISA. To confirm the clinical observation, we also studied MIF expression in prediabetic rats with impaired glucose
tolerance (IGT) and relationship between MIF and GRK2 expression in H9C2 cardiomyoblasts exposed to high glucose.
Results: Compared with healthy subjects, patients with diabetes have significantly increased levels of plasma MIF which was
further increased in diabetic patients with Left ventricular diastolic dysfunction (LVDD). The increased plasma MIF levels in
diabetic patients correlated with plasma glucose, glycosylated hemoglobin and urine albumin levels. We observed a
significant number of TUNEL-positive cells in the myocardium of IGT-rats but not in the control rats. Moreover, we found
higher MIF expression in the heart of IGT with cardiac dysfunction compared to that of the controls. In H9C2 cardiomyoblast
cells, MIF and GRK2 expression was significantly increased in a glucose concentration-dependant manner. Furthermore,
GRK2 expression was abolished by siRNA knockdown of MIF and by the inhibition of CXCR4 in H9C2 cells.
Conclusions: Our findings indicate that hyperglycemia is a causal factor for increased levels of pro-inflammatory cytokine
MIF which plays a role in the development of cardiomyopathy occurring in patients with type 2 diabetes. The elevated
levels of MIF are associated with cardiac dysfunction in diabetic patients, and the MIF effects are mediated by GRK2.
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Introduction
Cardiomyopathy and cardiac dysfunction is a frequent
complication in diabetic patients[1]. Diabetic patients develop a
characteristic cardiomyopathy of ventricular hypertrophy and
diastolic dysfunction which can be detected by cardiac tissue
Doppler[2]. Poirior et al has shown that left ventricular diastolic
dysfunction (LVDD) represent the first stage of diabetic cardio-
myopathy[3]. Previous studies have demonstrated that the
diastolic dysfunction and abnormal left ventricular mass can be
ameliorated by tight glycemic control[4], indicating that hyper-
glycemia is a critical factor in diabetic cardiomyopathy. In the
chronic state, high blood glucose induced by the effect of impaired
glucose tolerance (IGT), especially postprandial hyperglycemia,
may cause cardiac damage and dysfunction or apoptosis,
eventually lead to the development of heart failure [5,6].
It has been shown that a number of cytokine and inflammation
factors are abnormally expressed in diabetic myocardium and
contribute to myocardial fibrosis. Macrophage migration inhibi-
tory factor (MIF) is one of the cytokines that has been shown to be
increased in patients with type 2 diabetes. Importantly, MIF is
associated with impaired glucose tolerance in type 2 diabetes[7].
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(MMP9) which is involved in remodeling[8]. A recent report
indicate that MIF mediates late cardiac dysfunction after burn
injury[9]. Furthermore, MIF has been considered a cardiac-
derived myocardial depressant factor[10]. Previous in vitro studies
showing a role of MIF in inducing apoptosis in AC16 human
cardiomyocytes exposed to high glucose levels[11]. However, the
role of MIF in diabetic cardiomyopathy has not been studied in
vivo and the signaling pathways mediating MIF’s effect remains
unknown.
Desensitization of G protein–coupled receptors (GPCR) is
emerging as an important feature of several cardiovascular
diseases. G protein–coupled receptor kinase 2 (GRK2) plays a
key role in the regulation of a variety of these receptors, and its
cardiac expression levels are altered in pathological situations such
as chronic heart failure[12]. In the present study, we sought to
compare the circulating MIF levels in diabetic patients with or
without LVDD. Furthermore, we examined MIF expression in
prediabetic rats and in H9C2 cardiomyoblasts cells exposed to
high glucose level. In order to identify the downstream factors that
mediate MIF’s effect, we also studied the expression of GRK2 in
H9C2 exposed to high glucose and MIF.
Materials and Methods
Patient study
This study recruited 83 type 2 diabetes patients (aged 30–64
years; forty-seven males and thirty-six females, without evidence of
hypertension, coronary artery disease, congestive heart failure,
diabetic complications; and with a maximal treadmill exercise test
showing no ischemia), and 30 age-sex matched healthy adults. LV
diastolic function was evaluated by cardiac tissue Doppler
echocardiography, and systolic function was normal in all subjects.
Pseudonormal pattern of ventricular filling and E’/A’,1 was
regarded as LVDD. The diabetes subjects with normal left
ventricle diastolic function were used as diabetic controls. All
subjects had their fasting blood samples taken. The blood samples
were centrifuged, and plasma were separated and frozen at
270uC. The clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki, and approved
by the Research Ethics Committee of Guangdong General
Hospital (Guangzhou, China),the approval number was No. G-
DREC [2009]101. All subjects gave written consents to participate
in this study, and were told to follow only conventional medical
treatments without additional burden.
Plasma insulin concentrations were determined by ROCHE
Elecsys 2010 (ROCHE Diagnostics GmbH). The sensitivity of this
assay is 0.26 mU/ml, whereas the intraassay precision is 2.6% and
interassay precision is 5.8%. Plasma glucose, triglyceride, LDL
cholesterol, HDL cholesterol and total cholesterol levels were
measured by Synchron systems LX20 (Beckman Coulter, Full-
erton, CA). Glycated hemoglobin was determined using a
commercial kit (Bio-Rad DiaSTAT analysor, BIO-RAD Labora-
tories Inc. Hercules, CA). The homeostasis model assessment of
insulin resistance (HOMA-IR) was used as a substituted marker of
insulin resistance. HOMA-IR was calculated using the following
formula: HOMA-IR = fasting insulin (microunits per milliliter)6
fasting glucose (micromoles per liter)/135.
Animal Study
Sprague-Dawley (SD) rat were obtained at 6–8 wk of age from
Laboratory Animal Center of Sun Yat-sen University and
maintained in a specific pathogen-free environment. Commercial
chow and tap water were made available ad libitum. All animals
received a care in compliance with the Guide for the Care and Use
of Laboratory Animals of US National Research Council in 1996,
and the program was also approved by the research ethics
committee of Guangdong General Hospital, the approval number
was No. GDREC[2009]102(Animal). According to previous
reported procedures [13], the rats were randomly assigned to a
normal rat chow, or a high-fat diet. The normal mouse chow and
high-fat diet contained, respectively, 3% and 20% fat, 20% and
18% protein, 45% and 33% carbohydrate. There was an
adjunction of 5% salt in high-fat diet. For the IGT-rat, the tail-
vein was injected with 20 mg/kg streptozotocin (STZ, Sigma, St.
Louis, MO), and the drink-water was added by 0.04% N (G)-nitro-
L- arginine methyl ester (L-NAME, Sigma, St. Louis, MO) and
10% fructose(Archer Daniels Midland Comp, Decatur IL). After
4 wk, all rats were anesthetized with 4-6.25 mg/kg Diazepam and
2–3.5 mg/kg Ketamine. Whole hearts were removed, snap frozen
in liquid nitrogen, and stored at 280uC or fixed in 10% neutral-
buffered formalin for 24 h and placed in 70% ethanol.
The fasting blood glucose (FBG) levels and glucose tolerance of the
rats were detected at 4 wk. Briefly, animals were food-restricted
overnight and subjected to oral glucose tolerance test (OGTT) using a
glucose feeding (1 g/kg) by intragastric administration. Blood
(,0.25 ml) was collected from a cut at the end of the tail immediately
at 0, 15, 30, 60, 90 and 150 minutes after glucose administration. and
then the blood glucose (BG) was assayed by test strip (Roche, Accu-
Check, Germany) and assessment of area-under-the-curve (AUC) for
150 min of BG concentration used the following formula[14]:
AUCBG=7.5*BG0+15*BG15+22.5*BG30+30*BG60+45*BG90+30*
BG150.
Cardiac function was measured at 4 wk. The rats were sedated
with Ketamine, and left parasternal images were taken in the right
lateral decubitus position with a 13-MHz transducer (Acuson,
Mountain View, CA).
Cell culture study
H9C2 cardiomyoblast (ATCC, Manassas, VA) were cultured
with different concentrations of glucose (0, 5.5, 12.5, 25 and
33 mmol/L, adjusted the same osmotic pressure with manitol).
Total RNA was isolated at 6 h after glucose treatment from the
H9C2 cardiomyoblasts cell cultured in 6 wells plate using Trizol
Reagent. In addition, 24 h after glucose treatment, the cells were
split by cell disruption solution and incubated at 280uC for a
further 24 h to adequately extract soluble proteins. After melting,
the homogenates were disposed by ultrasonication, then centri-
fuged at 5,0006g, and the supernatant was collected and stored at
220uC until use.
AMD3100 (Sigma, St Louis, MO, USA) was used to inhibit
CXCR4 on H9C2 cells. Because CXCR4 has been recognized as
one part of MIF receptor complexes [15], this study was designed to
investigate whether GRK2 expression induced by high glucose is
mediated by MIF-CXCR4 pathway. First, H9C2 cells were pre-
treated with different concentrations of AMD3100 (0, 1, 2.5, 5,
10 mg/mL) for 1 h, and then cultured in 25 mMglucose medium for
24 h. Second, H9C2 cells were pre-treated with 5 mg/mLAMD3100
for 1 h, and then cultured in25 mM glucose medium for3, 6, 12, 24,
4 8h .T h el o wg l u c o s e( 5m M )w a su s e da st h en o r m a lc o n t r o l .T h e y
were then analyzed by western blotting for GRK2 expression. All
experiments were repeated at least three times.
Determination of plasma MIF
Plasma MIF was assayed by a sandwich enzyme-linked
immunosorbent assay using an antibody pair and recombinant
MIF from R&D Systems (Wiesbaden, Germany). The intra-assay
precision for this assay is 3.5%, and the interassay precision is
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lowest standard concentration measured in this assay was 30 pg/
ml. The mean for normal range for healthy subjects was
1.260.6 ng/ml (range: 0–2.3 ng/ml). There was no cross-
reactivity with seven recombinant proteins tested (macrophage
chemoatractant protein-1, TNF, matrix metalloproteinase-9,
interleukin-4, interferon-c, tissue factor, and soluble intercellular
adhesion molecule-1). All samples were assayed together in two
large batches.
Determination of MIF and GRK2 mRNA level in circulatory
lymphocytes
Total RNAwas isolatedfrom peripherallymphocyteswhich were
separated from peripheral blood using Trizol Reagent. In brief, the
real-time PCR assay includes two steps. Reverse transcription was
performed by using ThermoScript
TM RT-PCR system. PCR
conditions were 95uC for 3 min, followed by 34 cycles of 94uC
for 50 s, 58uC for 30 s and 72uC 45 s for MIF, and 36 cycles of
94uC for 50 s, 58uC for 40 s and 72uC 50 s for GRK2 in the Bio-
Rad MJ OPTICON-II apparatus. Fluorescence changes were
monitored with SYBR Green PCR Supermix (Bio-Rad) after every
cycle, and melting curve analysis was performed at the end of 35
cycles to verify PCR product identity. Each PCR reaction was
repeated three times, and the average median threshold cycle values
were used for analysis. To normalize RNA content, the GAPDH
was used as an internal control. The PCR primers were as follow:
GAPDH: sense: 59-GTG GGC CAT GAG GTC CAC-39;
antisense: 59-TCC ATG ACA ACT TTG GTA TCG T-39
(478 bp); MIF: sense: 59-TCA CCG CCT CGG CTT GTC A-39;
antisense: 59-ATG AAC TTT CTG CTG TCT TG-39 (198 bp);
GRK2: sense:59-TTC TCG AAG AGT GCC ACT G-39,
antisense: 59-CAT TCA TGG TCA GGT GGA TG-39 (202 bp).
Western blot assay
To measure the protein levels of MIF and GRK2 in H9c2
cardiomyoblasts cells treated with glucose, Protein was extracted
from cultured cells with ice-cold lysis buffer consisting of
50 mmol/L HEPES (pH 7.4), 1% Triton-X100, 2 mmol/L
sodium orthovanadate, 100 mmol/L sodium fluoride, 1 mmol/L
edetic acid (EDTA), 1 mmol/L phenylmethylsulphonyl fluoride
(PMSF), 10 mg/L aprotinin and 10 mg/L leupetin (Sigma, St
Louis, MO, USA). After centrifugation at 120006g centrifugation
for 5 min, the protein content of the supernatant was determined
using the Quick Start
TM Bradford assay (Bio-Rad, Hercules, CA).
Then, cellular protein extracts were separated by gradient
polyacrylamide gel electrophoresis (12–15%) and transferred to
polyvinylidene difluoride membranes (PVDF membranes). The
membranes was probed with primary polyclonal rabbit anti-MIF,
Table 1. Clinical features of study subjects.
Normal(n=30) DM (n=46) DM+LVDD(n=37)
Age(years) 40 (30–55) 48 (30–62) 51(37–64)
Disease period (months) 0 48 (11–99) 52 (14–166)
Body mass index (kg/m
2) 22.8561.87 23.8960.76 23.5865.64
Fasting blood glucose (mmol/L) 4.7762.81 10.2563.92** 9.6663.34**
Postglandial blood glucose (mmol/L) 6.0662.39 13.5864.72** 14.8765.66**
Glycosylated hemoglobin (%) 6.1961.55 8.5462.21* 9.5661.64*#
HOMA-IR 1.2260.67 1.7960.95* 1.8461.02*
Total cholesterol (mmol/L) 4.6860.79 4.7560.85 4.7160.91
Triglyceride (mmol/L) 1.1861.11 1.9861.66* 2.0561.91*
LDL (mmol/L) 2.2361.08 2.4360.97 2.5560.70
HDL (mmol/L) 1.2460.97 1.1160.68 1.1960.69
Urine albumin concentration (mg/mmol.Cr) 10.6967.44 17.14616.28* 35.18634.09**#
1Results are presented as mean 6SD, compared with Normal,
*p,0.05,
**p,0.01; Compared with DM,
#p,0.05.
2Normal: healthy subjects; DM: type 2 diabetes mellitus patients; DM+LVDD: DM patients with left ventricular diastolic dysfunction. The urine albumin concentration is
the ratio to creatinine (Cr).
doi:10.1371/journal.pone.0016239.t001
Table 2. The evaluation of left ventricular function in study
subjects.
Normal
(n=30)
DM
(n=46)
DM+LVDD
(n=37)
E/A ratio 1.4660.44 1.3760.42 0.6760.34**##
LVIDs (cm) 28.9663.61 25.1363.81* 25.9264.26*
LVIDd(cm) 46.3264.02 45.4763.13 41.3363.57*#
LVSD(cm) 7.8960.78 9.4760.99 10.4561.35*#
LVPWD(cm) 7.7160.95 8.0160.81 8.5761.18*
EF(%) 61.5568.07 60.869.7 46.067.8**##
1Compared to Normal,
*p,0.05,
**p,0.01; Compared to DM,
#p,0.05,
##p,0.01.
2E/A ratio: the mitral blood flow velocity during early diastole (E)/atrial
contraction (A); LVIDs: left ventricular internal diameter at end-systole; LVIDd:
left ventricular internal diameter at end-diastole; IVSD: interventricular septum
thickness at end-diastole; LVPWD: left ventricular posterior wall thickness at
end-diastole; EF: ejection fraction.
doi:10.1371/journal.pone.0016239.t002
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health control, *p,0.05, ** p,0.01; compared with diabetic patients without LVDD, #p,0.05.
doi:10.1371/journal.pone.0016239.g001
Figure 2. The levels of lymphocyte MIF mRNA (A) and GRK2 (B) in type 2 diabetic patients with or without LVDD. Results are presented
as mean 6 SD, compared with health control,*p,0.05, ** p,0.01; compared with diabetic patients without LVDD, #p,0.05.
doi:10.1371/journal.pone.0016239.g002
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(Santa Cruz, CA) according to the procedures recommended by
the manufacturers, followed by a goat anti-rabbit IgG–horse
radish peroxidase and mouse anti- goat IgG– horse radish
peroxidase, respectively. Immune reactivity was visualized with
ECL plus Western Blotting Detection reagents (Amersham
Biosciences, Buckinghamshire, UK) using procedures recom-
mended by the manufacturer, then the signals were quantified
by densitometry.
Construction of MIF siRNAs plasmid
Three candidate siRNAs targeting MIF gene were selected by
using the siRNA designing programme of the Ambion (Ambion
Inc, Austin, TX). The DNA templates for MIF siRNAs were
annealed by two complimentary oligonucleotide strands. The loop
sequence of the two DNA templates was TTCAAGAGA, with the
complimentary sequences at the bilateralis and two sticky end
sequences corresponding to the terminations of the linearized
pSilencer-4.1-neo. According to the targeting sequence of the MIF
siRNA, CAGGGTCTACATCAACTATTA, two single oligonu-
cleotide strands were designed and synthesized. The sequence of
the sense strand was 59-GAT CCG GGT CTA CAT CAA CTA
TTA TTC AAG AGA TAA TAG TTG ATG TAG ACC CTG
A-39, and the antisense strand was 59-AGC TTC AGG GTC
TAC ATC AAC TAT TAT CTC TTG AAT AAT AGT TGA
TGT AGA CCC G-39.
Plasmid transfection and siRNA Interference
Before the start of the experiment, 3610
5 H9C2 cells were
inoculated in 6-well plates. After the cell abundance reached 60%
to 70%, the MIF-siRNA plasmid was transfected into the cells by
using Lipofectamine 2000
TM reagent (Invitrogen, Carlsbad CA,
USA). A negative siRNA plasmid was used to control. In order to
observe the specificity, one of the transfected groups was treated
with 50 ng/mL rhMIF to neutralize the siRNA activity. The
recombinant human MIF (rhMIF) was cloned, expressed in
Escherichia coli, and purified from the soluble fraction of the cell
lysate as previous study[8]. This rhMIF contained ,10 pg of
endotoxin per microgram of recombinant protein, as determined
by the chromogenic Limulus amebocyte assay (Chromogenix,
Sweden).
Glycogen staining
Briefly, after deparaffinization and rehydration, the sections of
heart tissues were stained with periodic acid-Schiff’s reagent (PAS,
Polyscientific, Bay Shore, NY) for glycogen and finally counter-
stained with hematoxylin, according to the manufacturer’s
guidelines.
TUNEL staining
Heart tissues were fixed in 10% formalin, embedded in paraffin,
and sectioned at 5 mm. And in situ TUNEL detection kit from
Keygen (Nanjing, China) was used according to the manufactur-
er’s instructions. Briefly, after deparaffinization and rehydration,
the sections were treated with H2O2 and incubated with the
reaction mixture containing TdT and digoxigenin-conjugated
dUTP for 1 h at 37uC. Labeled DNA was visualized with
peroxidase-conjugated anti-digoxigenin antibody using 3,39-dia-
minobenzidine (DAB) as the chromogen. For negative control,
TdT was omitted from the reaction mixture.
Statistical analysis
Statistical analysis was carried out using SPSS13.0 software.
Continuous data are expressed as the mean 6 SD. Statistical
analysis was carried out using unpaired t test between diabetes
controls and diabetes with LVDD subjects. Correlation analysis
was performed using Spearman rank order correlation among
plasma MIF, glucose level, and HOMA-IR, and body mass index.
Results in vitro were analysis of variance (ANOVA) followed by
student’s-t-test. A p value of less than 0.05 was considered
significant.
Table 3. Comparison of biomarkers in control and IGT rats
(mean6SD).
Controls (n=6) IGT rats (n=6)
FBG (mmol/L) 4.2661.34 5.3761.49*
AUCBG (mol/LN150 min) 1.1460.37 1.5860.29*
CK-MB (U/L) 493.96186.1 2682.46894.9**
NT-proBNP (pg/ml) 65.6610.5 514.36204.1**
CRP (mmol/L) 2.7261.87 4.9761.99**
IGF-1 (pg/ml) 4068.36311.3 2991.56401.5*
MIF (ng/ml) 24.864.0 32.564.7*
*p,0.05,
**p,0.01 vs. controls.
FBG: Fasting blood glucose; AUCBG: area-under-the-curve of blood glucose in
oral glucose tolerance test; CK-MB: MB isoenzyme of creatine kinase; NT-
proBNP: N-terminal pro-brain natriuretic peptide; CRP: C-reactive protein; IGF-1:
insulin-like growth factor-1; MIF: macrophage migration inhibitory factor; IGT:
impaired glucose tolerance.
doi:10.1371/journal.pone.0016239.t003
Table 4. Echocardiographic assessment of cardiac function in
rats (mean6SD).
Controls (n=6) IGT rats (n=6)
LVDd (mm) 4.2160.21 5.6860.45*
LVDs (mm) 2.4360.08 3.7460.33*
EF (%) 81.6061.96 69.3262.83*
LVFS (%) 44.7861.87 34.3362.08*
HR (beats/min) 449.24616.21 428.1668.70*
PWd (mm) 2.9460.44 1.8860.18*
*p,0.05 vs. controls.
LVDd: left ventricular end diastolic dimension; LVDs: left ventricular end-systolic
dimension; EF: ejection fraction; LVFS: Left ventricular fractional shortening; HR:
heart rate; PWd: posterior wall diastolic; PWs: posterior wall systolic; IVSd:
interventricular septum in diastole; IVSs: interventricular septum in systole; IGT:
impaired glucose tolerance.
doi:10.1371/journal.pone.0016239.t004
Figure 3. Correlations of postglandial blood glucose (PBG), glycosylated hemoglobin (GHB) and urine albumin (uALB) levels with
plasma MIF respectively in diabetic patients with LVDD. The statistical analysis indicated that PBG, GHB and uALB level correlated with plasma
MIF in diabetic patients with LVDD (r=0.354, p,0.05; r=0.336, p,0.05; r=0.312, p,0.05, respectively).
doi:10.1371/journal.pone.0016239.g003
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Clinical characteristic of diabetic patients with LVDD
We found increased levels of blood glucose and triglyceride in
diabetic patients who also developed insulin resistance (HOMA-
IR). Higher levels of glycosylated hemoglobin, and albuminuria
were found in diabetic patients with LVDD compared to diabetic
patients without LVDD (Table 1). We found no significant
differences between the two groups of patients on parameters such
as age, body mass index, disease period, HOMA-IR and total
cholesterol.
Left ventricular diastolic function was evaluated by tissue
Doppler echocardiography. The ratio of the mitral blood flow
velocity during early diastole to atrial contraction (E/A) in diabetes
with LVDD decreased significantly compared to healthy subjects
or diabetic patients without LVDD (0.6760.34 vs 1.4660.44 or
1.3760.42, p,0.01). We also observed reduced ejection fraction
(EF) in diabetic patients with LVDD compared to healthy subjects
or in diabetic patients without LVDD (46.067.8 vs 61.5568.07 or
60.869.7, p,0.01) (Table 2).
MIF levels are altered in diabetic patients with LVDD
We found higher concentrations of MIF in the plasma of DM
subjects compared to healthy subjects (DM with LVDD 3.3960.96,
without LVDD 2.5960.59 vs. Normal 2.0560.49 ng/ml, p,0.05).
The plasma MIF concentrations of patients with type 2 diabetes with
LVDD were significantlyhigher than that of diabeticpatients without
LVDD (3.3960.96 vs 2.5960.59 ng/ml, p,0.05) (Figure 1).
Real-time quantitative RT-PCR assay revealed that the level of
MIFmRNA expression inperipherallymphocytesfrom the diabetic
patients with LVDD was significantly higher than that of diabetic
patients without LVDD (Figure 2A) and mRNA expression of
GRK2 followed a similar pattern as MIF (Figure 2B). Furthermore,
postglandial blood glucose (PBG), glycosylated hemoglobin (GHB)
and urine albumin (uALB) level correlated with plasma MIF in
diabetic patients with LVDD (r=0.354, p,0.05; r=0.336,
p,0.05; r=0.312, p,0.05, respectively) (Figure 3).
FBG levels and MIF levels are increased in IGT-rats
FBG levels of IGT-rats were higher than those of controls at
4 wk (Table 3). The glucose metabolism of rats was evaluated by
Figure 4. Comparison of myocardial pathology between control (A, C, E) and IGT (B, D, F) rats. A—B: Cardiac glycogen identified by PAS
staining, the glycogen granules were stained into prunosus, cellular nuclei were stained into blue; C—D: macrophage migration inhibitory factor
(MIF) detected by immunohistochemistry, the MIF was stained into brown; E—F: The apoptosis of myocardial cells detected by TUNEL, the brown
showed apoptotic cells, the blue showed nuclei.
doi:10.1371/journal.pone.0016239.g004
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that of controls (p,0.05). The data indicate that the glucose
metabolism of IGT-rats was imbalanced such that glucose couldn’t
be utilized or metabolized normally in many organs, including
heart. Furthermore the levels of MIF and CRP were also higher in
IGT rats than that of the controls (p,0.05).
Echocardiography assay for the cardiac function in IGT-
rats
Cardiac function in IGT-rats and controls was assessed by
echocardiography. After 4 wk, the EF and LVFS in IGT-rats were
much lower than that of the controls, indicating that the cardiac
diastole and construction were impaired in IGT-rats. LVDd,
LVDs and PWd were also abnormal in IGT-rats, suggesting the
ongoing cardiac remodeling in IGT-rats. (Table 4).
The myocardium of IGT-rats is characterized by increased
apoptosis and MIF expression
We found increased storage of glycogen in the heart of IGT-rat
compared to that of the control animals (Figure 4A and 4B).
Glycogen was mainly stored in the cardiac perivascular tissues of
IGT-rat. MIF expression is higher in the heart of IGT with cardiac
dysfunction compared to that of the controls (Figure 4C and 4D).
We also observed a significant number of TUNEL-positive cells
(45%67%) in the myocardium of IGT-rats but not in the control
rats. (Figure 4E and 4F). Western blot analysis showed higher
expressions of MIF and GRK2 in IGT-rats than that in controls
(Figure 5).
High glucose induced GRK2 expression is mediated by MIF via
CXCR4 pathway.
Using Western blot, we examined the protein levels of MIF and
GRK2 in H9C2 cardiomyoblasts with high glucose exposure. Our
data showed glucose induced the expression of both MIF and
GRK2 in a dose dependent pattern (Figure 6). To find out
whether glucose induced GRK2 expression is mediated by MIF,
MIF silencing was performed 12 hours before glucose treatment.
We found that glucose-induced GRK2 expression was abolished
by MIF siRNA (Figure 7). These data indicate that glucose
induced GRK2 expression is mediated by MIF. Furthermore, MIF
expression induced by high glucose was accompanied by the
phosphorylation of NF-kB (Figure 6), suggested that NF-kB
pathway may be involved in high glucose induced MIF expression.
To determine whether CXCR4 pathway is involved in MIF
signaling and subsequent GRK2 expression, we treated H9C2
cells with high glucose in the presence or absence of CXCR4
inhibitor AMD3100. Compared with untreated cells, GRK2
protein expression increased at 24 h after high glucose treatment,
but this increased GRK2 expression was abolished by various
concentrations of CXCR4 inhibitor AMD3100, especially by 5
Figure 5. Western blot analysis of MIF and GRK2 protein expressions in the rat hearts. A: Representative western blots of heart lysates
showing the expression of MIF and GRK2. B: Quantitative detection by densitometric analysis and normalized to b-actin (mean6SD, n=4). Compared
with control:*p ,0.05, **p,0.01.
doi:10.1371/journal.pone.0016239.g005
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GRK2 expression in H9C2 cells in normal condition, but
AMD3100 pretreatment prevented high glucose induced GRK2
(Figures 8B and D).
Discussion
The major findings of the present study are that plasma levels of
MIF is increased in diabetic patients with LVDD and MIF levels
Figure 6. Western blot analysis of MIF and GRK2 expression, and the phosphorylation levels of NF-kB in H9C2 cells. H9C2
cardiomyoblasts were treated with various concentrations of glucose (0, 5.5, 12.5, 25 and 33 mmol/L) for 24 hours. A: Representative blot map; B:
Quantitative analysis of MIF and GRK2 expression; C: Quantitative analysis of the ratio of phosphorylated NF-kB.
doi:10.1371/journal.pone.0016239.g006
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hemoglobin and urine albumin. We demonstrated that both MIF
and GRK2 mRNA levels are increased in circulatory lymphocytes
from diabetic patient with LVDD. Our data indicate that MIF and
GRK2 expression can be induced in H9C2 cells when exposed to
high glucose levels. We further showed that the expression of
GRK2 is induced by MIF. To our knowledge, this is the first
report that GRK2 expression is upregulated in diabetic patients
with LVDD and that GRK2 is regulated by MIF.
MIF is a pleiotropic cytokine that plays a crucial role in innate
immune immunity as well as stress responses [16]. MIF is also
associated with insulin resistance[17]. It has been shown previously
that systemic concentrations of MIF are elevated in patients with
obesity, impaired glucose tolerance and type 2 diabetes[18]. Recent
studies also suggested a direct link between MIF and cardiovascular
disease[19]. MIFis produced abundantly by various cells in all types
of human atherosclerotic lesions[20,21]. Genetic deletion and
antibody inhibition studies established a causal link between MIF
and atherosclerosis [22]. These previous reports are in line with our
findings that MIF may be a causal factor of left ventricular diastolic
dysfunction in patients with type 2 diabetes.
The mechanism through which MIF exerts its atherogenic
properties may involve chemokine-like functions. It has been
reported that MIF activates both chemokine receptors CXCR2
and CXCR4 and thereby mediates the recruitment of inflamma-
tory cells like monocytes and lymphocytes [15,23]. In the present
study, we demonstrate that MIF could also exert its effect via the
upregulation of GRK2, and the elevated GRK2 levels can be
blocked by specific CXCR4 inhibitor, AMD3100. Therefore,
over-expression of GRK2 induced by high glucose may be
mediated by MIF-CXCR4 signaling pathway.
Heart failure is characterized by abnormalities at multiple levels
in 7TM receptor signaling pathways such as chronic receptor
desensitization of b-adrenergic receptors resulting in reduced
receptor responsiveness. Because the expression and activity of
GRK2 are increased in multiple animal models of heart disease
and in human heart failure, it has been suggested that enhanced
GRK2 activity can explain the concomitantly decreased receptor
responsiveness[24]. GRK2 is a family of serine/threonine kinases
that specifically phosphorylate agonist-occupied GPCRs[25]. The
phosphorylation event leads to the uncoupling of beta-adrenergic
and angiotensin receptors from their associated G protein and
initiate the sequestration of the receptors.
In order to investigate the pathogenesis of cardiac dysfunction
induced by IGT, we studied the cardiac glucose metabolism,
apoptosis and expressions of MIF and GRK2 in animals. Our data
showed that more glucose was converted to glycogen in the
myocardial tissues of IGT rats than that in controls. These data
suggest that in IDT rat, high glucose has modified myocardial
energy metabolism and resulted in augmented fatty acid and
decreased glucose consumption [26]. Consequently, superfluous or
extra glucose that myocardium can’t utilize is transformed into
glycogen which is stored in hearts, resulting cardiac dysfunction
[27]. Interestingly, perivascular myocardium of IGT rat was a
main place for glycogen deposit, and it was inferred that the high
blood glucose might first damage the areas close to blood vessels.
Our data further showed that cardiac apoptosis in prediabetes
state may lead to cell death and removal, thereby contributing to
the cardiac function damage. Furthermore, we observed that the
expression level of GRK2 was higher in the IGT rats than in
controls. Our findings are in line with previous reports that
abnormal up-regulation of GRK2 can chronically and constantly
Figure 7. The effect of MIF knockdown on glucose-induced GRK2 expression. H9C2 cells were incubated with glucose (25 mmol/L) for
different time. The cells were treated with either glucose, or combination with MIF siRNA. GRK2 expression was assessed by Western blot analysis. A:
Representative blot map; B: Quantitative analysis of GRK2 expression.
doi:10.1371/journal.pone.0016239.g007
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failure development [28].
Previous studies have shown that MIF may be induced by
oxidative stress [29]. We and others have demonstrated that high
glucose is a strong oxidative stress and apoptosis inducing factor
[30]. It has been shown that MIF expression can be induced by
oxidative stress through a NF-kB mediated mechanism [29,31].
The cardiac dysfunction resulting from high glucose may be
mediated partly by MIF, and NF-kB signaling pathway may be
involved in this process [31]. In addition, the insulin resistance and
type-2 diabetes were characterized by an increase in lipolysis and
FFA concentrations, and elevated FFA levels also induced an
increase in MIF [32]. Therefore, IGT caused a lot of disorder
which come together to cause chronic inflammation, especially
increase MIF, and finally result in myocardial damage.
In conclusion, our data suggest that MIF are involved in the
pathogenesis of LVDD in patients with type 2 diabetes and GRK2
may play a role in mediating MIF’s effect. These findings provided
new insights into the role of inflammation in the development of
diabetic cardiomyopathy which has a potential therapeutic
implication.
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